This rendering shows Trelleborg’s plans for its Malta expansion. [Illustration courtesy of Trelleborg]
Trelleborg Healthcare & Medical announces a substantial investment to expand its European biopharmaceutical manufacturing capabilities in Malta. This follows a multimillion-dollar investment initiated in 2022 to expand biopharma capacities in North America.
Linda Muroski, President of Trelleborg Healthcare & Medical, says: “The site will initially add over 4,000 square feet of cleanroom space and focus on silicone tubing and braided hose with options to extend capabilities in the future. This is our second biopharma-focused manufacturing space alongside our BioPharma Center of Excellence in Northborough, Massachusetts in the U.S.”
The Malta site is one of Trelleborg’s largest manufacturing sites in Europe with a history of more than 60 years in advanced elastomeric solutions. Currently the main site in Hal Far consists of three buildings and construction has already begun on a fourth adjacent block. The facility is set for completion by the end of 2023 with production starting early 2024.
Florance Veronelli, Global Business Development Lead for Biopharmaceutical, says: “The investment is a key milestone in our biopharmaceutical strategy of being a global partner for growth. With increased capacity and local accessibility, we can offer our customers the same capabilities in two different regions. This results in shorter lead times, more flexibility, increased speed to market, and best cost, especially when it comes to customers with a large demand for bulky products like tubing.”
Trelleborg is known for supplying original equipment manufacturers and pharmaceutical companies with a broad range of products and capabilities for single- and multi-use biopharmaceutical applications. The company’s portfolio ranges from its highly reliable and proven silicone PharmaTube™ and hose to custom silicone and rubber-molded parts, O-Rings, seals, bearings, and composite products, all customizable into ready-to-use solutions.
About Trelleborg Healthcare & Medical and Trelleborg Group
Trelleborg Healthcare & Medical helps pharmaceutical and medical device companies improve patient quality of life. It does this by forming lasting partnerships with customers to develop innovative, reliable engineered polymer solutions for demanding medical, biotech and pharmaceutical applications. From a single global source, backed by the expertise of a worldwide engineering and manufacturing network, it partners with its customers in all stages of development, from concept to serial production, providing the optimum solutions to meet all their partners polymer- based healthcare & medical application challenges. Trelleborg Healthcare & Medical combines a number of operations from within Trelleborg Group that are focused on this industry. www.trelleborg.com/healthcare
Trelleborg is a world leader in engineered polymer solutions that seal, damp and protect critical applications in demanding environments. Its innovative solutions accelerate performance for customers in a sustainable way. The Trelleborg Group’s continuing operations had annual sales of about SEK 30 billion (EUR 2.83 billion, USD 2.98 billion) in 2022 and operations in about 50 countries. The Group comprises three business areas: Trelleborg Industrial Solutions, Trelleborg Sealing Solutions and Trelleborg Wheel Systems. The Trelleborg share has been listed on the Stock Exchange since 1964 and is listed on Nasdaq Stockholm, Large Cap. www.trelleborg.com
The opinions expressed in this news release are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.
Source link : https://www.medicaldesignandoutsourcing.com/trelleborg-expansion-biopharma-manufacturing-footprint-europe-malta/
Author :
Publish date : 2023-02-06 08:00:00
Copyright for syndicated content belongs to the linked Source.
